Visit https://www.peervoice.com/BRJ860 to view the entire programme with slides. After completing “State of the Science in CKD: New Treatment, New Outcomes”, participants will be able to: Explain the rationale for SGLT2 inhibition in patients with chronic kidney disease (CKD), with or without type 2 diabetes (T2DM); Summarise the goals of therapy for patients with CKD, based on latest data; Apply updated strategies to the management of CKD, with the goal of improving outcomes and fostering a multidisciplinary approach